General MedicationsSUBCUTANEOUSGeneric
REDITREX
METHOTREXATE
Standard Dose
7.5MG/0.3ML (7.5MG/0.3ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview REDITREX is listed in Drugs@FDA under application 210737 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.3ML (7.5MG/0.3ML) Sponsor NORDIC GRP Submission history Latest submission status date: 2023-03-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview REDITREX is listed in Drugs@FDA under application 210737 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.3ML (7.5MG/0.3ML) Sponsor NORDIC GRP Submission history Latest submission status date: 2023-03-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.